Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04317417 · ClinicalTrials.gov registry record · NA

MOST EMPOWER: Optimizing An Emotion Regulation Intervention

A NA study of Cancer, sponsored by Wake Forest University Health Sciences.

Completed
Registry status
NA
Development phase
352
Enrollment target
3
Study locations

NCT04317417 is a NA study of Cancer that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 352 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (90% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04317417, a NA study of Cancer, has completed, sponsored by Wake Forest University Health Sciences.

COMPLETED
Registry status
NA
Development phase
352 participants
Enrollment target
3
Study locations

Study Summary

This purpose of this study is to test a digital health intervention that may promote well-being among young adult cancer survivors. Investigators hope to learn more about wellness and health-related quality of life among young adult cancer survivors by promoting well-being and teaching skills for healthy coping and mood management.

Conditions Studied

Interventions

  • BEHAVIORAL EMPOWER

Study Locations (3)

Illinois

  • Northwestern University Feinberg School of Medicine - Chicago

North Carolina

  • Wake Forest Baptist Comprehensive Cancer Center - Winston-Salem

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 352 participants
Start Date 2022-01-06
Est. Completion 2025-04-30
Phase NA

Sponsor

Wake Forest University Health Sciences

1,140 total trials

What the Registry Record Tells You About NCT04317417

The ClinicalTrials.gov registry entry for NCT04317417 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 352 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (90% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which EMPOWER is the first listed.

NCT04317417 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Illinois, North Carolina, Texas.

Frequently Asked Questions

What is clinical trial NCT04317417 about?

NCT04317417 is a clinical study titled "MOST EMPOWER: Optimizing An Emotion Regulation Intervention". This purpose of this study is to test a digital health intervention that may promote well-being among young adult cancer survivors. Investigators hope to learn more about wellness and health-related quality of life among young adult cancer survivors by promoting well-being and teaching skills for he...

What is the current status of trial NCT04317417?

This trial is currently completed. It is a NA study. The enrollment target is 352 participants. The study started on 2022-01-06. Estimated completion is 2025-04-30.

What conditions does trial NCT04317417 study?

This clinical trial studies the following conditions: Cancer.

What interventions are being tested in trial NCT04317417?

The interventions under investigation include: EMPOWER (BEHAVIORAL).

Who is sponsoring clinical trial NCT04317417?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04317417 being conducted?

This trial has 3 study locations across Illinois, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.